Jpmorgan Chase & CO Theravance Biopharma, Inc. Transaction History

Jpmorgan Chase & CO

  • $1.27 Trillion
  • Q1 2025

A detailed history of Jpmorgan Chase & CO transactions in Theravance Biopharma, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 156,817 shares of TBPH stock, worth $2.18 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
156,817
Previous 219,568 28.58%
Holding current value
$2.18 Million
Previous $2.07 Million 32.24%
% of portfolio
0.0%
Previous 0.0%

Shares

20 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

May 12, 2025
SELL
$8.44 - $10.47 $529,618 - $657,002
-62,751 Reduced 28.58%
156,817 $1.4 Million
Q4 2024

Feb 12, 2025
SELL
$7.93 - $10.08 $375,176 - $476,894
-47,311 Reduced 17.73%
219,568 $2.07 Million
Q3 2024

Dec 26, 2024
BUY
$7.66 - $10.25 $58,369 - $78,105
7,620 Added 2.94%
266,879 $2.15 Million
Q3 2024

Nov 08, 2024
BUY
$7.66 - $10.25 $58,369 - $78,105
7,620 Added 2.94%
266,879 $2.15 Million
Q2 2024

Dec 26, 2024
SELL
$8.29 - $9.92 $63,169 - $75,590
-7,620 Reduced 2.86%
259,259 $2.2 Million
Q2 2024

Aug 12, 2024
BUY
$8.29 - $9.92 $1.89 Million - $2.27 Million
228,396 Added 740.03%
259,259 $2.2 Million
Q1 2024

Dec 26, 2024
SELL
$8.22 - $11.59 $1.94 Million - $2.74 Million
-236,016 Reduced 88.44%
30,863 $276,000
Q1 2024

May 10, 2024
SELL
$8.22 - $11.59 $108,717 - $153,289
-13,226 Reduced 30.0%
30,863 $276,000
Q4 2023

Dec 26, 2024
SELL
$8.58 - $11.4 $1.91 Million - $2.54 Million
-222,790 Reduced 83.48%
44,089 $495,000
Q4 2023

Feb 12, 2024
SELL
$8.58 - $11.4 $31,068 - $41,279
-3,621 Reduced 7.59%
44,089 $495,000
Q3 2023

Nov 14, 2023
SELL
$8.38 - $10.44 $26,430 - $32,927
-3,154 Reduced 6.2%
47,710 $411,000
Q2 2023

Aug 11, 2023
SELL
$10.16 - $11.92 $1.64 Million - $1.93 Million
-161,663 Reduced 76.07%
50,864 $526,000
Q1 2023

May 18, 2023
BUY
$9.87 - $11.44 $493,736 - $572,274
50,024 Added 30.78%
212,527 $2.31 Million
Q1 2023

May 11, 2023
SELL
$9.87 - $11.44 $506,775 - $587,386
-51,345 Reduced 24.01%
162,503 $1.76 Million
Q4 2022

Feb 13, 2023
BUY
$9.65 - $11.34 $132,542 - $155,754
13,735 Added 6.86%
213,848 $2.4 Million
Q3 2022

Nov 14, 2022
SELL
$8.39 - $10.22 $60,760 - $74,013
-7,242 Reduced 3.49%
200,113 $2.03 Million
Q2 2022

Aug 11, 2022
BUY
$8.41 - $10.34 $286,469 - $352,211
34,063 Added 19.66%
207,355 $1.88 Million
Q1 2022

May 11, 2022
SELL
$8.33 - $12.96 $265,043 - $412,361
-31,818 Reduced 15.51%
173,292 $1.66 Million
Q4 2021

Feb 10, 2022
SELL
$7.42 - $11.05 $208,939 - $311,156
-28,159 Reduced 12.07%
205,110 $2.27 Million
Q3 2021

Nov 12, 2021
BUY
$6.77 - $14.41 $1.58 Million - $3.36 Million
233,269 New
233,269 $1.73 Million

Others Institutions Holding TBPH

# of Institutions
137
Shares Held
48.5M
Call Options Held
0
Put Options Held
11.6K
View Full List

About Theravance Biopharma, Inc.

TBPH Quotes by TradingView
  • Ticker TBPH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 66,782,400
  • Market Cap $930M
  • Description
  • Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also inc...
More about TBPH
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email